Clinical Trials Directory

Trials / Completed

CompletedNCT02891655

KERatoconus and Metalloproteinases InvesTigation

Status
Completed
Phase
Study type
Observational
Enrollment
23 (actual)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Corneal stromal thinning observed in keratoconic eyes could result from an increased synthesis of MMP at the level of the anterior stroma and the corneal epithelium induced by an overexpression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and Galectin-3 by epithelial cells. A differential expression of EMMPRIN, Galectin-3 and metalloproteinases (MMP) may be observed between the apex of the keratoconus and the peripheral cornea. Highlighting the implication of EMMPRIN and Galectin-3 could lead to the development of specific inhibitors to slow or to stop keratoconus evolution.

Conditions

Interventions

TypeNameDescription
OTHERimmuno-histo-chemical analysisin vitro immuno-histo-chemical analysis of corneal epithelium

Timeline

Start date
2016-12-02
Primary completion
2020-06-26
Completion
2020-11-26
First posted
2016-09-07
Last updated
2020-12-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02891655. Inclusion in this directory is not an endorsement.